|Bid||0.0750 x N/A|
|Ask||0.0800 x N/A|
|Day's Range||0.0750 - 0.0800|
|52 Week Range||0.0750 - 0.0800|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Toronto, Ontario--(Newsfile Corp. - October 30, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that the Company has entered into a convertible debenture extension and amendment agreement (the "Amending Agreement") dated October 29, 2020 with Quinsam Capital Corporation (the "Lender"). The Amending Agreement amends certain terms of the 10% convertible debenture dated November 1, 2017 in the principal amount of $262,500 and the 10% convertible debenture dated December ...
Neuroscientist, Healthcare Technology Entrepreneur to Lead Aion Through Important Next Phase Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that the Company has named James W.G. Thompson, Ph.D. as its new president.Dr. Thompson is an accomplished neuroscientist and healthcare technology entrepreneur with over 20 years industry experience. Most recently he co-founded Evoke Neuroscience, Inc., a healthcare technology company founded in 2009 ...
Toronto, Ontario--(Newsfile Corp. - September 18, 2020) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 9,090,907 units ("Units") at a price of $0.055 per Unit for gross proceeds of approximately $500,000 (the "Offering"). The proceeds of the Offering will be used for general working capital purposes.Each Unit is comprised of one common share ("Common Share") of ...